Tango Therapeutics Inc
TNGX6.755USD
+0.225+3.45%
交易中 （美东）报价延迟15分钟
730.27M总市值
亏损市盈率 TTM
关于 Tango Therapeutics Inc 公司
Tango Therapeutics, Inc. 是一家临床阶段的生物技术公司，致力于发现新型药物靶点并提供用于治疗癌症的精准医疗。该公司利用合成致死的遗传原理来发现和开发针对癌症关键靶点的疗法。这包括将精准肿瘤学靶点的范围扩展到新领域，例如肿瘤抑制基因缺失及其对癌细胞逃避免疫细胞杀伤能力的贡献。其主要项目 TNG908 是一种甲硫腺苷 (MTA) 协同抑制剂，可抑制蛋白质精氨酸甲基转移酶 5 (PRMT5)，旨在选择性地作用于甲硫腺苷磷酸化酶 (MTAP) 缺失的癌细胞。其 TNG260 是同类首创的抑制元件 1 沉默转录 (CoREST) 的辅抑制剂。该公司的项目还包括 TNG348 和 TNG462。 TNG348 是泛素特异性蛋白酶 (USP1) 的变构抑制剂。
公司简介
公司代码TNGX
公司名称Tango Therapeutics Inc
上市日期Sep 03, 2020
CEODr. Barbara Weber, M.D.
员工数量155
证券类型Ordinary Share
年结日Sep 03
公司地址201 Brookline Avenue
城市BOSTON
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02215
电话18573204900
网址https://www.tangotx.com/
公司代码TNGX
上市日期Sep 03, 2020
CEODr. Barbara Weber, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Chief Financial Officer
Chief Financial Officer
98.90K
+6.68%
Dr. Adam S. Crystal, M.D., Ph.D.
Dr. Adam S. Crystal, M.D., Ph.D.
President - Research and Development
President - Research and Development
69.70K
+5.90%
Mr. Douglas Barry
Mr. Douglas Barry
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary
23.55K
-64.32%
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Mr. Alexis Borisy
Mr. Alexis Borisy
Independent Chairman of the Board
Independent Chairman of the Board
11.25K
+125.00%
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Independent Director
Independent Director
6.25K
--
Mr. Elizabeth Hickin
Mr. Elizabeth Hickin
Vice President, IR and Corporate Communications
Vice President, IR and Corporate Communications
--
--
Dr. Barbara Weber, M.D.
Dr. Barbara Weber, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. John Ketchum
Mr. John Ketchum
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Chief Financial Officer
Chief Financial Officer
98.90K
+6.68%
Dr. Adam S. Crystal, M.D., Ph.D.
Dr. Adam S. Crystal, M.D., Ph.D.
President - Research and Development
President - Research and Development
69.70K
+5.90%
Mr. Douglas Barry
Mr. Douglas Barry
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary
23.55K
-64.32%
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Mr. Alexis Borisy
Mr. Alexis Borisy
Independent Chairman of the Board
Independent Chairman of the Board
11.25K
+125.00%
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
11.25K
+125.00%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月2日 周六
更新时间: 8月2日 周六
持股股东
股东类型
持股股东
持股股东
占比
Third Rock Ventures, LLC
15.55%
TCG Crossover Management, LLC
9.90%
EcoR1 Capital, LLC
9.81%
Boxer Capital Management, LLC
9.58%
Farallon Capital Management, L.L.C.
6.63%
Other
48.53%
持股股东
持股股东
占比
Third Rock Ventures, LLC
15.55%
TCG Crossover Management, LLC
9.90%
EcoR1 Capital, LLC
9.81%
Boxer Capital Management, LLC
9.58%
Farallon Capital Management, L.L.C.
6.63%
Other
48.53%
股东类型
持股股东
占比
Investment Advisor
34.87%
Hedge Fund
24.69%
Investment Advisor/Hedge Fund
19.20%
Venture Capital
16.29%
Corporation
11.03%
Individual Investor
1.57%
Research Firm
1.15%
Family Office
0.65%
Private Equity
0.51%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
311
118.45M
109.28%
-17.53M
2025Q1
320
116.84M
107.85%
-22.33M
2024Q4
310
116.06M
107.37%
-22.45M
2024Q3
292
115.54M
108.00%
-9.29M
2024Q2
286
112.62M
105.54%
-13.62M
2024Q1
280
112.63M
105.80%
-9.88M
2023Q4
261
107.66M
105.42%
-11.67M
2023Q3
235
102.78M
102.09%
+4.42M
2023Q2
224
81.67M
92.47%
-10.11M
2023Q1
216
83.27M
94.51%
-3.16M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Third Rock Ventures, LLC
16.86M
15.55%
-194.17K
-1.14%
Apr 01, 2025
TCG Crossover Management, LLC
10.74M
9.9%
--
--
Mar 31, 2025
EcoR1 Capital, LLC
10.63M
9.81%
--
--
Mar 31, 2025
Boxer Capital Management, LLC
10.38M
9.58%
--
--
Mar 31, 2025
Farallon Capital Management, L.L.C.
7.18M
6.63%
+2.57M
+55.76%
Jun 06, 2025
Nextech Invest, Ltd.
5.53M
5.11%
--
--
Mar 31, 2025
Gilead Sciences Inc
4.85M
4.48%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
3.88M
3.58%
-98.30K
-2.47%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.74M
3.45%
-110.35K
-2.87%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
3.31M
3.06%
-33.10K
-0.99%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
iShares Micro-Cap ETF
0.08%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
iShares Biotechnology ETF
0.03%
ProShares UltraPro Russell2000
0.02%
Global X Russell 2000 ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Proshares Ultra Russell 2000
0.02%
ProShares Hedge Replication ETF
0.02%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.91%
iShares Micro-Cap ETF
占比0.08%
ProShares Ultra Nasdaq Biotechnology
占比0.06%
Invesco Nasdaq Biotechnology ETF
占比0.06%
iShares Biotechnology ETF
占比0.03%
ProShares UltraPro Russell2000
占比0.02%
Global X Russell 2000 ETF
占比0.02%
iShares Russell 2000 Value ETF
占比0.02%
Proshares Ultra Russell 2000
占比0.02%
ProShares Hedge Replication ETF
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
